



Diagnósticos da América S.A.

Investor Relations
Av. Juruá, 434 - Alphaville, Barueri - SP
55 11 4197-5410
55 11 4197-5509
ir@danet.com.br
www.diagnosticosdaamerica.com.br



MATERIAL FACT

Diagnósticos da América S.A. Publicly-Held Company with Authorized Stock Corporate Tax Payer (CNPJ) no. 61.486.650/0001-83

Pursuant to CVM Instruction no. 358/2002 and the applicable laws in effect, Diagnósticos da América S.A. (Bovespa: DASA3) hereby informs its stockholders and the market of the following:

1. On June 15, 2006, Diagnósticos da América S.A. ("DASA") acquired 300,000 quotas or 100% of the capital stock of Laboratório Louis Pasteur Centro de Medicina Laboratorial Ltda. ("LabPasteur"), a company that provides clinical analysis services in the city of Fortaleza, State of Ceará;
2. The said quotas are valued at R\$ 13,000,000.00 and they will be paid for in full with DASA's own resources. The amount due to the former partners of LabPasteur, namely R\$ 9,500,000.00, will be settled in cash. The remaining R\$ 3,500,000.00 will be withheld in escrow deposit accounts for as long as six years, for the following purposes: R\$ 2,000,000.00 to cover potential contingencies, and R\$ 1,500,000.00 related to the continuation of LabPasteur's former partners' conduction of activities. An existing net debt of R\$ 77,000.00 will be deducted from the transaction value;
3. The real estate property where LabPasteur headquarters is located in the city of Fortaleza and appraised at R\$ 3,220,000.00 has not been included in this transaction and will become a property of LabPasteur's former partners. This real state property has been leased by LabPasteur and will also be of pledged as security to cover potential contingencies;
4. LabPasteur was founded in 1989 to provide clinical analysis services in the city of Fortaleza (Ceará state). Certified by the Brazilian Society of Clinical Pathology (PALC), it is the largest clinical laboratory in the city, with 14 patient service centers, and it serves approximately 1,100 patients per day (roughly 27,000 per month). LabPasteur posted gross sales of R\$ 14.7 million in 2005 and R\$ 15.5 million between April 2005 and March 2006;
5. This acquisition will allow DASA to establish its first clinical analysis operation in the Northeast of Brazil. The city of Fortaleza constitutes a market of 2.2 million inhabitants, 33% of whom are covered by private medical assistance plans;
6. The operation was approved in a meeting held on this date by DASA's Board of Directors. Because the purchase price does not represent a significant investment for DASA as per Act no. 6.404/76, Article 256, Subsection I, Paragraph 1, this transaction does not have to be submitted to a Special Shareholders' Meeting for ratification. The acquisition of LabPasteur will also be submitted to the Brazilian Antitrust Commission (CADE) for approval.

São Paulo, June 16, 2006

Marcelo Marques Moreira Filho
Chief Executive Officer and Investor Relations Officer